Options Are Looking Quite Attractive: Kosmos Energy Ltd. (KOS), Clovis Oncology, Inc. (CLVS)

WARBURG PINCUS & CO., Director, sold 104,500,000 shares of the Kosmos Energy Ltd. (NYSE:KOS) in an exchange that happened on November 26th, 2018. The stock was sold at an average price of $5.40 per share, amounting to a transaction worth $563,935,000. The sale was made public in a document filed with the SEC. Additionally, Director WARBURG PINCUS & CO. sold 50,359,103 shares of this stock in a transaction that took place on November 26th, 2018. The stock was sold at an average price of $5.40 per share, for a total exchange amounting to $271,763,261. After the transaction, the Director WARBURG PINCUS & CO. currently holds 16,090,787 shares of the company’s stock, which is worth approximately $83189369.

With this stock price’s latest movement, it is now -46.97% away from its 1-year high and 0.39% higher than its 1-year low price. In the past seven days, the stock price volatility for Kosmos Energy Ltd. was 6.07%, whereas its volatility in the past 30 days has been 6.58%. This public company’s stock also has a beta score of 1.94. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.

Kosmos Energy Ltd. (NYSE:KOS) most recently published its quarterly earnings results. The firm posted -$0.23 earnings per share (EPS) for the three-month period, missing analysts’ consensus estimate of -$0.23. The publicly-traded organization reported revenue of $250.22 million for the quarter, compared to the average analyst forecast calling for $246.21 million, which was surpassing the analyst consensus estimate.

Shares of Kosmos Energy Ltd. (KOS) plunged -1.34%, amounting to a loss of -$0.07 per share, to finish the regular trading session at $5.17 on Thursday 12/06/2018. After beginning the session at $5.11, shares of Kosmos Energy Ltd. reached as high as $5.18 during the day, while hitting a 1-day low of $4.92. Trade volume reached 6,153,767 shares against this stock’s average daily volume of 3.09M shares, with a total float of 297.41M. As a consequence of the price decrease, Kosmos Energy Ltd. now has a current market value of 2.30B.

Clovis Oncology, Inc. (NASDAQ:CLVS) subtracted -0.60% to its trading price by the close of the most recent session, dropping from its previous closing price of $19.99 to $19.87. This stock increased in value by 17.78% during the last 7-day period, and experienced a gain of 38.95% over the past 30-day period. In the past three months, this stock’s price lost by -43.62% , and subtracted -56.39% to its price during the last six months of trading. CLVS demonstrated a yearly price loss of -65.56% , while its year-to-date (YTD) price performance has been down -70.78% . This stock’s price changed by +72.78% compared to its 90-day low, and moved down -44.56% comparing to its 90-day high price.

Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the CLVS stock as “Sell”. In the short-term, Clovis Oncology, Inc. (CLVS) has a 20-day average volume of 2,725,030 shares and short-term indicators sets the CLVS stock as “ 40% Buy ” on average basis. In the medium-term, CLVS stock has a 50-Day average volume of 3,127,954 shares and medium-term indicators gave the average rating of “ 25% Sell ”, while in the long-term period the FB stock has a 100-Day average volume of 2,037,439 shares. On average, long-term indicators rated the stock as “67% Sell ”. The overall picture from all short, medium and long-term indicators sets the CLVS stock as “16% Sell ” on average basis.

Recently, multiple brokerages have sent out reports on CLVS. Leerink Partners, for example, Upgrade its rating on shares of Clovis Oncology, Inc. from “Mkt Perform ” to a “ Outperform”according to a research note from Tuesday December 4th, 2018. while giving the stock a “ Neutral” from “Overweight ” rating, as stated in a research report from Wednesday, October 31st, 2018. Piper Jaffray, on the other hand, Resumed a “Neutral” rating on this stock in a research note dated Friday, October 19th, 2018.

In other news related to Clovis Oncology, Inc. stock, 0.00% shares of CLVS held by institutions. The total number of institutions who held the CLVS shares was 292, according to most recent SEC filling. During the past quarter, total 64,154,002 shares held by institutions with the net change of 4,608,916 shares. In the meantime, 30 new institutions bought the shares of Clovis Oncology, Inc. for the first time and 51 institutions sold all their holdings in the company’s common stock. 128 institutions increased their investment in the CLVS stock and 130 institutions decreased their investment in the Clovis Oncology, Inc. (CLVS)’s stock during the last quarter.